Abstract
Background: There is conflicting data regarding the use of hydroxychloroquine (HCQ) in COVID-19 hospitalized patients. Objective: To assess the efficacy of HCQ in increasing SARS-CoV-2 viral clearance. Design: Retrospective observational study. Setting: Cleveland Clinic Abu Dhabi. Participants: Hospitalized adult patients with confirmed SARS-CoV-2 infection. Intervention: None. Measurements: The primary outcome was the time from a confirmed positive nasopharyngeal swab to turn negative (defined as two consecutive negative results 24 hours apart). Results: 34 patients were included. The time to SARS-CoV-2 negativity was significantly longer in patients who received HCQ compared to those who did not (17 [13–21] vs. 10 [4–13] days, p=0.023). HCQ remained independently associated with slower clearance after adjustment for confounders. Conclusion: HCQ was associated with slower viral clearance in patients with mild to moderate disease.
Introduction
In the early stages of the COVID-19 pandemic, the medical community faced an urgent need for effective therapeutic interventions. Hydroxychloroquine (HCQ), an antimalarial and anti-inflammatory agent, emerged as a primary candidate based on promising in vitro studies and preliminary clinical reports. However, as clinical data accumulated, results remained inconsistent, with some studies suggesting benefit and others highlighting potential risks, such as QTc prolongation. This study investigates the impact of HCQ on the duration of viral shedding—a critical metric for understanding both the drug's efficacy and the patient's infectious period.
Methods
Researchers conducted a retrospective observational study at Cleveland Clinic Abu Dhabi, analyzing 34 consecutive adult patients hospitalized with confirmed SARS-CoV-2 between March 1 and March 25, 2020.
Treatment and Protocol
Of the cohort, 21 patients received a standard HCQ regimen (400 mg twice daily on day one, followed by 400 mg daily for 10 days), while 13 patients did not receive the drug. The primary endpoint was the time from the initial positive nasopharyngeal swab to "negativity," defined as two consecutive negative RT-PCR tests performed 24 hours apart.
Statistical Analysis
To account for differences in baseline disease severity, the authors employed multivariable linear regression. This analysis adjusted for potential confounders, including the presence of pneumonia, the requirement for oxygen therapy, and the presence of symptoms at admission.
Results
Viral Clearance Duration
The study found a statistically significant difference in the time to viral clearance. Patients treated with HCQ required a median of 17 days (IQR 13–21) to achieve negativity, whereas the control group achieved clearance in a median of 10 days (IQR 4–13) (p=0.023).
14-Day Negativity Rates
By the 14th day of observation, the disparity was stark: only 47.8% (14/23) of patients in the HCQ group had tested negative, compared to 90.9% (10/11) of patients in the control group (p=0.016).
Multivariable Analysis
Even after adjusting for clinical factors such as pneumonia and oxygen therapy, HCQ treatment remained an independent predictor of delayed viral clearance. In terms of safety, the low-dose regimen used in this study was well-tolerated, with no significant adverse events or heart rhythm issues reported in this small cohort.
Discussion
The Pharmacokinetic Gap
A key insight from this study involves the pharmacological feasibility of HCQ as an antiviral. The authors performed a calculation based on the drug's volume of distribution and the concentration required to inhibit the virus in laboratory settings ($EC_{50}$). They estimated that a patient would need to ingest approximately 356 tablets (200mg each) to reach effective antiviral levels in the blood. This suggests that standard clinical doses are likely insufficient to exert a direct antiviral effect.
Immunomodulatory Interference
HCQ is known for its ability to delay cellular immune responses. The authors hypothesize that by dampening the body's natural inflammatory response, the drug may inadvertently allow the virus to persist longer in the upper respiratory tract. This is supported by the finding that HCQ did not significantly improve inflammatory markers, such as C-reactive protein or ferritin, compared to the control group.
Limitations
This study is limited by its retrospective design and a small sample size of 34 patients, which increases the risk of selection bias and limits statistical power. Furthermore, the findings are specific to patients with mild-to-moderate disease and cannot be generalized to severe or critical cases requiring intensive care.
Conclusion
Contrary to early expectations, this study suggests that hydroxychloroquine is associated with a slower viral clearance in patients with mild-to-moderate COVID-19. While these findings were preliminary at the time of the study, they align with subsequent large-scale randomized controlled trials, such as RECOVERY and SOLIDARITY, which ultimately found no clinical benefit for HCQ in hospitalized COVID-19 patients.
Summary updated